Amylin Pharmaceuticals Inc. and Eli Lilly and Co. have agreed to develop a pen device for delivering exenatide to diabetics, an arrangement in which they will share the initial capital investment of about $216 million, with Lilly making 60 percent of that investment. (BioWorld Today) Read More
